{"id":295569,"date":"2025-08-28T00:00:00","date_gmt":"2025-08-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algopn0001-2023-biopharma-osteoarthritic-pain-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-03-31T10:25:13","modified_gmt":"2026-03-31T10:25:13","slug":"algopn0001-2025-biopharma-osteoarthritic-pain-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algopn0001-2025-biopharma-osteoarthritic-pain-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Osteoarthritic Pain &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Osteoarthritic Pain (US)"},"content":{"rendered":"<p>Osteoarthritic (<abbr title=\"osteoarthritic\">OA<\/abbr>) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments, including intra-articular agents, <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s, antidepressants, opioids, and <abbr title=\"antiepileptic drug\">AED<\/abbr>s, are prescribed to alleviate the pain and enhance mobility, but more-effective, well-tolerated alternatives are needed. In this crowded and largely generic market, a deep understanding of treatment patterns is essential for the successful introduction of a novel analgesic.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"osteoarthritic\">OA<\/abbr> pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"osteoarthritic\">OA<\/abbr> pain patients?<\/li>\n<li>How has Zilretta been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"osteoarthritic\">OA<\/abbr> pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"osteoarthritic\">OA<\/abbr> pain patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Pacira Biosciences, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa<\/p>\n<p><strong>Key drugs: <\/strong>Zilretta, NSAIDs, gabapentin, intra-articular corticosteroids, celecoxib, Xtampza ER, Qutenza, Nucynta, tramadol<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-295569","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoarthritic-pain","biopharma-therapy-areas-osteoarthritis","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295569\/revisions"}],"predecessor-version":[{"id":402980,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295569\/revisions\/402980"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}